Change in Omega 3 Index in Healthy Adults With OmeGo or a Standard Omega-3 Oil Supplement
← catalyst calendarSponsored by Hofseth Biocare ASA (industry) · HBC.OL — their whole pipeline →.
Phase
Not applicable
Status
Completed
Study type
Interventional
Design
Randomized · None · Prevention
Enrollment
96actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-18 | actual | When the study began enrolling |
| Primary completion | 2025-12-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-05 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Supplementation in Healthy Adults to Assess Impact on Omega 3 Index and Cardiometabolic Health
Interventions
- Dietary supplement: whole salmon oil — also filed as CARDIO oil
- Dietary supplement: Cod liver oil
Primary outcome
what the primary-completion date above is the date OFTo assess and compare the bioavailability of a natural salmon oil with that of a standard omega-3 supplement
measured 18 weeks
Publications
- PMID 30954305 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · HBC.OL's whole pipeline · Catalyst calendar · Every registered study · What changed